GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (STU:P0J) » Definitions » Common Stock

Aptamer Group (STU:P0J) Common Stock : €2.40 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Aptamer Group Common Stock?

Aptamer Group's quarterly common stock increased from Dec. 2023 (€0.54 Mil) to Jun. 2024 (€0.55 Mil) and increased from Jun. 2024 (€0.55 Mil) to Dec. 2024 (€2.40 Mil).

Aptamer Group's annual common stock stayed the same from Jun. 2022 (€0.08 Mil) to Jun. 2023 (€0.08 Mil) but then increased from Jun. 2023 (€0.08 Mil) to Jun. 2024 (€0.55 Mil).


Aptamer Group Common Stock Historical Data

The historical data trend for Aptamer Group's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group Common Stock Chart

Aptamer Group Annual Data
Trend Mar19 Mar20 Jun22 Jun23 Jun24
Common Stock
0.03 0.03 0.08 0.08 0.55

Aptamer Group Semi-Annual Data
Mar19 Mar20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only 0.08 0.08 0.54 0.55 2.40

Aptamer Group Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Aptamer Group Business Description

Traded in Other Exchanges
Address
Innovation Way, Windmill House, York, GBR, YO10 5BR
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics. The Group represents a single operating segment being research and experimental development of biotechnology. It operates in United Kingdom, Europe, USA and other; Geographically earning maximum revenue from USA.

Aptamer Group Headlines

No Headlines